Piramal Pharma received a $360 million investment from US private equity company Carlyle Group in October 2020 in exchange for a 20% share. Piramal Pharma includes the contract development and manufacturing organisation, called the Piramal Pharma Solutions (PPS), which contributes three-fifths to the revenue.from Industry-Economic Times
Read The Rest:economictimes...
